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Pediatric nephrology covers a large ﬁeld of medical develop-
ments, including genetics, care strategies, and renal preser-
vation. Most of the pediatric kidney diseases are congenital,
some of them familial with a precise heredity. Growing, the
children will be adult patients emphasizing the importance
of better knowledge by the nephrologist of this kidney
disease, to optimize transition from pediatric to adult care.
T h e r e f o r e ,t h i ss p e c i a li s s u ei so fm a j o ri n t e r e s tf o r“ a l l . ”I t
was only possible to do this “issue” with the partnership of
many “Friends.”
Several Topics Are “Invited Reviews Resulting from Recognized
Expert Teams. The “Hemolytic uremic syndrome: new devel-
opments in pathogenesis and treatment”b yP .N i a u d e ta n dO .
Boyer can be divided into two forms, typical and atypical
HUS. Postdiarrhea HUS, that is, typical D+ (Shiga-toxin
enterohemorrhagic Escherichia coli (EHEC) or Shigella),
generally of good prognosis is the most common form of
HUS in children accounting for 90 percent of all cases.
Atypical HUS (aHUS) is a heterogeneous disorder which is
responsible for only 10 percent of cases in children. Throm-
botic microangiopathy may aﬀect other organ systems,
including the central nervous system, with poorer prognosis.
In the past 15 years, mutations in complement regulators
of the alternative pathway have been identiﬁed in almost
60% of cases, leading to excessive complement activation.
Eculizumab, a monoclonal antibody binding to C5, has been
used in patients with aHUS on native kidney or recurrence
of aHUS after transplantation with very encouraging results.
The “The history of cystinosis: lessons for clinical man-
agement”b yP .G o o d y e ri sm a r k e db yaf e ws u d d e nl e a p s
forward in our understanding rather than by a sustained
research eﬀort fuelled by the larger research community.
Major conceptual breakthroughs include (a) its discovery
in 1903, (b) recognition of the renal Fanconi syndrome,
(c) realization that tissue accumulation of cystine reﬂects a
defective channel in the lysosomal membrane, (d) transla-
tion of this discovery to trials of cysteamine, (e) discovery of
the CTNS gene, and (f) report of successful stem cell therapy
in the cystinotic mouse.
The “Primary hyperoxalurias” as marked by P. Cochat
et al. are inborn errors in the metabolism of glyoxylate
and oxalate. Early initiation of conservative treatment,
including high ﬂuid intake, inhibitors of calcium oxalate
crystallization, and pyridoxine in responsive cases, can help
to maintain renal function in compliant subjects. In end-
stage renal disease patients, the best outcomes have been
achieved with combined liver-kidney transplantation which
corrects the enzyme defect.
In the paper by J. A. Sayer et al., the “nephronophthisis”
is recognized as a ciliopathy. NPHP is a recessive monogenic
disorder [19], meaning that two mutations (homozygous or
compound heterozygous) in a single gene are suﬃcient to
cause disease. Thirteen genes have been identiﬁed in aﬀected
families with NPHP, and these genes currently allow 30%
o fc a s e sw i t hN P H Pt ob e“ s o l v e d ”i nt e r m so fam o l e c u l a r
diagnosis. NPH is a leading genetic cause of established renal
failure (ERF) in children and young adults.2 International Journal of Nephrology
The “Renal mitochondrial cytopathies”a r eag r o u po f
rarediseasesthatarecharacterizedbyfrequentmultisystemic
involvement and extreme variability of phenotype, including
renalinvolvement.Mostfrequentlypatientspresentatubular
defect that is consistent with complete De Toni-Debr´ e-
Fanconi syndrome in most severe forms. More rarely,
patients present with chronic tubulointerstitial nephritis,
cystic renal diseases, or primary glomerular involvement.
The “Molecular and genetic basis of inherited nephrotic
syndrome” describes the novel concept of the glomerular ﬁl-
tration barrier, highly dynamic slit diaphragm proteins. The
“Nephrotic syndrome in children: from bench to treatment”
allows a review of the clinical management of NS in children.
Most of the cases are steroid sensitive, but ﬁfty percents of
the latter recur frequently and necessitate a prevention of
relapses by nonsteroid drugs. But, their long-term prognosis
is overall good. On the contrary, steroid-resistant nephrotic
syndrome (SRINS) leads often to end-stage renal failure.
The “Recurrent focal segmental glomerulosclerosis: a dis-
crete clinical entity” describes that some FSGSs are caused by
mutations podocyte slit diaphragm genes, that is, hereditary
FSGS. Thereby, it is increasingly clear that the steroid-
resistant form of FSGS that recurs in the renal allografts (R-
FSGSs) constitutes a distinct clinical entity.
The “Primary molecular disorders and secondary biolog-
ical adaptations in Bartter syndrome” describes the Bartter
syndrome as a hereditary disorder that has been character-
ized by the association of hypokalemia, alkalosis, and the
hypertrophy of the juxtaglomerular complex with secondary
hyperaldosteronism and normal blood pressure. The genetic
causes of Bartter syndrome primarily aﬀect molecular struc-
turesdirectlyinvolvedinthesodiumreabsorptionatthelevel
of the Henle loop.
The “Acute renal replacement therapy in pediatrics”g i v e s
out the current knowledge on the dialysis modalities: when
to apply and, how to apply.
Chronic dialysis remains a life event for most of the
children on end-stage renal disease despite the growing place
of preemptive kidney transplantation. “Peritoneal dialysis
tailored to pediatric needs” and “Optimal hemodialysis pre-
scription: do children need more than a urea dialysis dose?”
oﬀer a review on the necessarily optimized dialysis strategies
for children based on collaborative clinical experiences. The
concept of the “adapted automatic peritoneal dialysis” is
described, as well as the place for a “convective volume” to
add to the limited urea dialysis dose. “Daily” hemodiaﬁltra-
tion appears as an optimal package to promote statural catch
up growth.
S e v e r a lT o p i c sR e ﬂ e c tO r i g i n a lE x p e r i e n c e s . This special issue
covers several original experiences: “Once-daily tacrolimus
extended-release formulation: 1 year after conversion in sta-
ble pediatric kidney transplant recipients,”“ The hypona-
tremic hypertensive syndrome in a preterm infant: a case of
severe hyponatremia with neurological sequels,”“ Depressive
symptomatology in children and adolescents with chronic
renal insuﬃciency undergoing chronic dialysis,”“ (Pro)renin
receptor in kidney development and disease,” and “Urinary
angiotensinogen as a biomarker of nephropathy in childhood.”
Together, the lecturers should improve their “pediatric
nephrology” knowledge, from bench to bedside.
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